

Ministry of Health

Health Programs and Delivery Division

Drug Submission Status

Report for January 2026

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via an HPDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Auro Pharma Inc.	Auro-Nintedanib	Ofev	NINTEDANIB	100 mg	capsule	02526891
Auro Pharma Inc.	Auro-Nintedanib	Ofev	NINTEDANIB	150 mg	capsule	02526905
Sanis Health Inc.	Prucalopride	Resotran	PRUCALOPRIDE	1 mg	tablet	02559005
Sanis Health Inc.	Prucalopride	Resotran	PRUCALOPRIDE	2 mg	tablet	02559013
Ascend Laboratories Ltd.	ASN-Rasagiline	Azilect	RASAGILINE MESYLATE	0.5 mg	tablet	02489120
Ascend Laboratories Ltd.	ASN-Rasagiline	Azilect	RASAGILINE MESYLATE	1 mg	tablet	02489139
Jamp Pharma Corporation	Jamp Valacyclovir	Valtrex	VALACYCLOVIR	1000 mg	tablet	02558858